Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorundrostat + SGLT2i in Hypertension and CKD with Albuminuria
NCT06150924Phase 2Completed
- Sponsor
- Mineralys Therapeutics
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lorundrostat in hypertension (HTN), chronic kidney disease (CKD), sponsored by Mineralys Therapeutics. Started Dec 2023; status: completed.
02
Drugs
lorundrostat
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06150924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06150924.